H Rosing
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Jörger M, Beijnen J, Cerny T, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P, Doodeman V, Cats A, Boot H, Huitema A, Schellens J. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2015; 75:763-72.
13.02.2015Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
13.02.2015Cancer Chemother Pharmacol 2015; 75:763-72
Jörger Markus, Beijnen J H, Cerny Thomas, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P H M, Doodeman V D, Cats A, Boot H, Huitema A D R, Schellens J H M
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
Jörger M, Huitema A, Koeberle D, Rosing H, Beijnen J, Hitz F, Cerny T, Schellens J, Gillessen Sommer S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 2013; 73:113-24.
29.10.2013Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
29.10.2013Cancer Chemother Pharmacol 2013; 73:113-24
Jörger Markus, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz Felicitas, Cerny Thomas, Schellens J H M, Gillessen Sommer Silke
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.
18.05.2011Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
18.05.2011Cancer Chemother Pharmacol 2011; 69:25-33
Jörger Markus, Beijnen J H, Huitema A D R, Rosing H, Vainchtein L D, Jansen R S, Smits P H M, Doodeman V D, Baas P, Burgers J A, Schellens J H M
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
Jörger M, Huitema A, Huizing M, Willemse P, de Graeff A, Rosing H, Schellens J, Beijnen J, Vermorken J. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. British journal of clinical pharmacology 2007; 64:622-33.
01.11.2007Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
01.11.2007British journal of clinical pharmacology 2007; 64:622-33
Jörger Markus, Huitema A D R, Huizing M T, Willemse P H B, de Graeff A, Rosing H, Schellens J H M, Beijnen J H, Vermorken J B
Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate
Brouwers E, Tibben M, Rosing H, Hillebrand M, Jörger M, Schellens J, Beijnen J. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of mass spectrometry : JMS 2006; 41:1186-94.
01.09.2006Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate
01.09.2006Journal of mass spectrometry : JMS 2006; 41:1186-94
Brouwers E E M, Tibben M M, Rosing H, Hillebrand M J X, Jörger Markus, Schellens J H M, Beijnen J H
Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry
Brouwers E, Tibben M, Jörger M, van Tellingen O, Rosing H, Schellens J, Beijnen J. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and bioanalytical chemistry 2005; 382:1484-90.
01.08.2005Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry
01.08.2005Analytical and bioanalytical chemistry 2005; 382:1484-90
Brouwers E E M, Tibben M M, Jörger Markus, van Tellingen O, Rosing H, Schellens J H M, Beijnen J H